Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
-
 
WKN: A3CSHQ / Name: Alzamend Neuro Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Alzamend Neuro Inc. Stock

So far the community has only identified positive things for Alzamend Neuro Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Alzamend Neuro Inc. in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients: https://mms.businesswire.com/media/20231211519845/en/1965628/5/Next-Generation_Lithium_Product_for_PTSD_Photo_12112023.jpg
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients


Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients: https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients


Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement: https://mms.businesswire.com/media/20210804005491/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement


Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”)